BioCryst Pharmaceuticals, Inc. (BCRX) Stock

BioCryst Pharmaceuticals, Inc. (BCRX) is a Healthcare stock trading at $9.68 (as of 2026-08-20), with a market capitalization of $2.47B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

BioCryst Pharmaceuticals develops novel oral small-molecule medicines. It markets peramivir injection for acute uncomplicated influenza and ORLADEYO for hereditary angioedema, and is developing BCX9930, BCX9250, and Galidesivir for complement-mediated diseases, fibrodysplasia ossificans progressiva, and multiple RNA virus infections, respectively.

Understand BioCryst Pharmaceuticals, Inc.: how it makes money

BioCryst Pharmaceuticals develops and sells oral small-molecule medicines and related treatments, earning revenue mainly from ORLADEYO (hereditary angioedema) and RAPIVAB (IV peramivir for acute uncomplicated influenza), plus smaller partner and other revenues.

The company’s economics are structurally driven by whether commercial product revenues, primarily ORLADEYO, can scale enough to offset substantial operating expenses, since gross margin is high but operating margin is deeply negative.

Revenue by segment (latest quarter)
Orladeo (ORLADEYO)$0.2B
Rapavab stockpile$0.0B
Partner Tori$0.0B
Other revenues$0.0B

Business quality (Solid): The provided facts show strong gross margin with significant operating losses, but the operating drivers are mostly represented by ORLADEYO-related revenue, and the rest of the revenue detail is limited.

Bull case

  • ORLADEYO is the main revenue source in the provided breakdown: In the latest period, ORLADEYO-related revenue (Orladeo) represents the largest reported component of revenue.
  • Pipeline products could expand future revenue opportunities: BioCryst is developing BCX9930 (Phase II for complement-mediated diseases) and BCX9250 (Phase I for a specified indication), which could broaden its long-term product base if clinical development progresses.

Bear case

  • Operating losses remain severe versus current revenue scale: The company reports a deeply negative operating margin for the latest period, indicating operating expenses far exceed operating gross profit.
  • Clinical trial execution and timelines are uncertain: BCX9930 is in Phase II and BCX9250 is in Phase I, so progress and potential outcomes are not guaranteed, and future adoption is inherently uncertain.
Valuation — source: SEC EDGAR (first-party)
Price$9.68
Market Cap$2.47B
Price / Sales3.58
FCF Yield-1.2%
DCF Value (model)$20.15
DCF Upside vs Price108.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$874.84M
Net Margin30.2%
Revenue Growth (YoY)94.1%
EPS Growth (YoY)-393.0%
FCF Growth (YoY)-749.0%
Financial Health — source: SEC EDGAR
Altman Z-Score2.58 (grey)
Piotroski F-Score7/9 (strong)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($215.64M)
Institutional Holders Tracked10
Congressional Trades (recent)4
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCharles K. Gayer
Employees580
CountryUS
IPO Date1994-03-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Iovance Biotherapeutics, Inc. (IOVA)
  • Tarsus Pharmaceuticals, Inc. (TARS)
  • Beam Therapeutics Inc. (BEAM)
  • Kodiak Sciences Inc. (KOD)
  • ADMA Biologics, Inc. (ADMA)
  • Hemab Therapeutics Holdings, Inc. (COAG)
  • Vericel Corporation (VCEL)
  • Taysha Gene Therapies, Inc. (TSHA)
BCRX earnings history · BCRX institutional & insider holders · BCRX KPIs & operating metrics · BCRX financials · BCRX investor presentations & press releases · BCRX SEC filings · BCRX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.